Nostrum Signs Licensing Deal with IMTECH
Nostrum will develop these new thrombolytics in association with one of its affiliates, Symmetrix Biotech, which is based in Mumbai, India.
Nostrum had earlier licensed Clot Specific Streptokinase (CSSK) in July 2006 from IMTECH Efficacy of CSSK bolus dose has been established in monkeys where it successfully re-perfused a freshly occluded artery while protecting blood fibrinogen levels, maintaining the normal blood pressure and not causing any incidence of bleeding.
Currently, preclinical toxicological studies in monkeys are being carried out for CSSK, and human clinical trials are expected to begin by the middle of the year 2011. As with CSSK, these novel thrombolytics being licensed currently will also be developed as single bolus dose.
The license agreement was earlier signed by Nirmal Mulye, president of Nostrum and Girish Sahni, director of IMTECH in New Delhi, India.
Nirmal Mulye said: “These novel, next generation thrombolytics are clot specific plasminogen activator proteins, and each one of these molecules has a uniquely different value-added properties such as longer half-life in blood circulation and re-occlusion prevention during heart attack. Moreover, these unique properties of the molecules will help to effectively mitigate a number of systemic side effects, such as bleeding, usually associated with the prevalent thrombolytic protein molecules in the market today.
“Our collaboration with CSIR is an example of successful public-private partnership. This is our third collaboration with IMTECH/ CSIR. Clearly they have been developing world-class technologies and setting an example of pursuing commercially viable innovations.”
Will the agreement benefit Nostrum?
Have your say and discuss with your peers on the InfoGrok community.
Participate by posting your comments now.